Author

Khandoker Usran Ferdous

University of Arkansas for Medical Sciences

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

Aleksandra CiosiD· 2 shared Bolni Marius NagaloiD· 2 shared Elizabeth A. RaupachiD· 2 shared Mitesh J. BoradiD· 2 shared Natalie M. ElliottiD· 2 shared Alex T Baker· 1 shared Alexei G. BasnakianiD· 1 shared Alicja Joanna UrbaniakiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Aleksandra CiosORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response

Mulu Z. Tesfay, Aleksandra Cios, Zetao Cheng, Khandoker Usran Ferdous, Randal S. Shelton, Bahaa Mustafa, Natalie M. Elliott, Elizabeth A. Raupach, Camila Simões, Isabelle Racine Miousse, Alicja Joanna Urbaniak, Michael Bauer, Eric R. Siegel, Steven R. Post, Jean Christopher Chamcheu, , Bolni Marius Nagalo

Oncolytic virus-based delivery of an alloantigen improves antitumor immunity and synergizes with immune checkpoint inhibitors in pancreatic cancer.

Journal for ImmunoTherapy of Cancer · May 1, 2026Peer-reviewedCancer Biology

Repeat Systemic Delivery of Cross-Neutralization Resistant Synthetic Vesiculoviruses Immunomodulates the Tumor Microenvironment

Natalie M. Elliott, Benjamin Luke Kendall, Souyma Dutta, Daipayan Sarkar, John Vant, Jill Thompson, Elizabeth A. Raupach, Christopher Shin, Khandoker Usran Ferdous, Aleksandra Cios, Kenneth H. Buetow, Chelsae R Watters, SangKon Oh, Autumn J. Schulze, Alex T Baker, , Mitesh J. Borad

A glycoprotein-engineered vesiculovirus platform circumvents neutralizing antibodies, enabling repeat intravenous dosing and sustained anti-tumor immunity in preclinical models.

bioRxiv · Aug 1, 2025 · PreprintMolecular Biology